WhiteLab Genomics
PrivateLast Round
Series B
Oct 6, 2026
Total Funding Raised
$46.54M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
WhiteLab Genomics operates in Healthcare & Life Sciences and is based in Paris. Its latest recorded funding round was a Series B round in October 2026.
WhiteLab Genomics is a biotechnology company that provides an AI-powered platform to accelerate and de-risk the design and development of gene, cell, and RNA therapies.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
WhiteLab Genomics Comparables
Compare WhiteLab Genomics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| METiS TechBio | 83% | |
| Dyno Therapeutics | 83% | |
| Shape Therapeutics | 83% |
For institutional investors. Book with your work email.
WhiteLab Genomics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 6, 2026 | ||||
| Early Funding | Jan 30, 2025 | ||||
| Series A | Sep 13, 2022 | ||||
| Accelerator | Jan 1, 2022 | ||||
| Grant | Jul 9, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
WhiteLab Genomics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Blast.club | Series B |
| Atlantic Vantage Point | Series B |
| EIT Health | Grant |
| Y Combinator | Accelerator, Series A |
| Omnes Capital | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 6, 2026
$26M round led by Atlantic Vantage Point.
- Jul 24, 2026
Monthly visitors grew 31% MoM, reaching 4.4K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 23, 2026
WhiteLab Genomics, Inc. attends ESGCT 2026 in Oct '26, where its team presents four posters on genomic medicine design capabilities.
- expands_offices_inOct 8, 2026
WhiteLab Genomics, Inc. plans to strengthen its Boston operations and expand on the US West Coast while pursuing opportunities in Japan and South Korea and continuing its European activities.
- expands_offices_inOct 8, 2026
WhiteLab Genomics, Inc. plans to strengthen its Boston operations, expand on the US West Coast, pursue opportunities in Japan and South Korea, and continue its European activities.
- is_developingOct 8, 2026
WhiteLab Genomics, Inc. works to develop a portfolio of experimentally validated bio-assets that it can advance independently or with biopharmaceutical partners, while planning commercial expansion across international markets.
- partners_withOct 6, 2026
WhiteLab Genomics, Inc. partners with Sanofi Inc., with WhiteLab Genomics, Inc. set to present additional in vivo data from the collaboration at the upcoming ESGCT Annual Congress.
For institutional investors. Book with your work email.
WhiteLab Genomics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about WhiteLab Genomics's valuation, stock price, and market status.
Is WhiteLab Genomics a public or private company?
WhiteLab Genomics is a private company.
What is the current stock price of WhiteLab Genomics?
WhiteLab Genomics is a private company, so its shares have no public market price. Caplight tracks WhiteLab Genomics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is WhiteLab Genomics worth (valuation)?
Valuation information for WhiteLab Genomics is not publicly available.
Can I buy WhiteLab Genomics stock?
WhiteLab Genomics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was WhiteLab Genomics's last funding round?
WhiteLab Genomics's most recent funding round was Series B on October 6, 2026.
Who are the main investors in WhiteLab Genomics?
Key investors in WhiteLab Genomics include Atlantic Vantage Point, Omnes Capital.
Will WhiteLab Genomics IPO soon?
No public IPO plans have been announced for WhiteLab Genomics.
How can I track WhiteLab Genomics secondary market activity?
Caplight tracks bids, offers, and trades in WhiteLab Genomics's shares on secondary markets.